Literature DB >> 10761600

[Prevention of sickle cell crises with multiple phlebotomies].

N Bouchaïr1, P Manigne, A Kanfer, P Raphalen, M de Montalembert, I Hagege, A Verschuur, M Maier-Redelsperger, R Girot.   

Abstract

OBJECTIVES: Sickle cell disease patients suffering from frequent painful crises were submitted to phlebotomies in order to reduce hospitalization days due to pain, through hemoglobin (Hb) level reduction and iron deficiency in patients with an hemoglobin level equal to or above 9.5 g/dL. PATIENTS: Seven sickle cell disease patients (four SC, three SS), aged four to 24 years, were submitted to sequential phlebotomies during periods from 18 months to four years.
METHODS: The number of hospitalization days for crises was considered. The volumes and frequencies of phlebotomies were adjusted according to the patients ages, the hemoglobin concentrations and the serum ferritin levels.
RESULTS: One hundred and forty-four hospitalization days were recorded in the seven patients in the year preceding the treatment. During the study period, the annual numbers of hospitalization days were respectively 20, five, six and one. Mean hemoglobin concentration was 10.7 g/dL before phlebotomies and 8.8 to 9.2 g/dL during the four years of treatment. Mean corpuscular volume, mean corpuscular hemoglobin concentration and serum ferritin were also reduced. The volume of phlebotomies was 116 to 39 mL/kg/year according to the patients. COMMENTS AND
CONCLUSION: The striking decrease of the number of hospitalization days for all the patients suggests a closed relationship between therapy and clinical improvement. The mechanism of this effect is probably multifactorial: a) the concentration of Hb level is known to influence the blood viscosity and its decrease always improved rheology in sickle cell disease patients; b) the mean corpuscular hemoglobin concentration is a critical factor concerning the HbS molecule polymerization in sickle cell disease, and its slight reduction may have an important biological effect. We observed these two biological modifications in our patients and suggest that they mediate the clinical effects. The iron deficiency induced by phlebotomies has no evident deleterious consequence either on height and weight in the children or on intellectual performance in any patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761600     DOI: 10.1016/s0929-693x(00)88740-0

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  7 in total

1.  Hemoglobin sickle cell disease complications: a clinical study of 179 cases.

Authors:  François Lionnet; Nadjib Hammoudi; Katia Stankovic Stojanovic; Virginie Avellino; Gilles Grateau; Robert Girot; Jean-Philippe Haymann
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

3.  Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.

Authors:  Julia Zhe Xu; Swee Lay Thein
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

4.  Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.

Authors:  Sandhya R Panch; Yu Ying Yau; Kamille West; Karen Diggs; Tamsen Sweigart; Susan F Leitman
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157

5.  Clinical applications of therapeutic phlebotomy.

Authors:  Kyung Hee Kim; Ki Young Oh
Journal:  J Blood Med       Date:  2016-07-18

6.  [Fortuitous detection of composite heterozygous S/C sickle cell disease].

Authors:  Asmâa Biaz; Maroua Neji; Yousra Ajhoun; Samira El Machtani Idrissi; Abdellah Dami; Karim Reda; Zohra Ouzzif; Sanae Bouhsain
Journal:  Pan Afr Med J       Date:  2017-06-07

7.  Effects of nutritional intake on disease severity in children with sickle cell disease.

Authors:  Valentina Mandese; Francesca Marotti; Luca Bedetti; Elena Bigi; Giovanni Palazzi; Lorenzo Iughetti
Journal:  Nutr J       Date:  2016-04-30       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.